Salarius Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

DCOY$1.11+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Three Months EndedMarch 31
	2024	2023
Operating activities
Net loss	$(1,715,290)	$(5,340,773)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,107	1,669
Equity-based compensation expense	77,508	203,345
Changes in operating assets and liabilities:
Grants receivable	—	1,480,490
Prepaid expenses and other assets	175,052	280,728
Accounts payable	111,104	627,576
Accrued expenses and other current liabilities	(3,436)	(422,470)
Net cash used in operating activities	(1,353,955)	(3,169,435)
Financing activities
Proceeds from issuance of equity securities, net	38	336,682
Payments on note payable	(172,788)	—
Net cash provided by financing activities	(172,750)	336,682
Net decrease in cash, cash equivalents and restricted cash	(1,526,705)	(2,832,753)
Cash, cash equivalents and restricted cash at beginning of period	5,899,910	12,106,435
Cash, cash equivalents and restricted cash at end of period	$4,373,205	$9,273,682
Supplemental disclosure of cash flow information:
Non-cash investing and financing activities:
Cash paid for interest	$4,019	$—
Common stock issued for in-process research and development technology	$—	$25,000

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.